Thus, the aim of our study was to shed light on the relevance of survivin as a biomarker according to the “REporting Recommendations for Tumour MARKer Prognostic Studies (REMARK)” and to further evaluate its role as therapeutic target in LPS. The gene discussed is BIRC5; the disease is neoplasm.